Why Exact Sciences Doesn't Have Much to Worry About With Declining COVID Testing

Exact Sciences (NASDAQ: EXAS) recently announced its first-quarter results. The company easily beat Wall Street expectations with some help from its COVID-19 testing business. In this Motley Fool Live video recorded on May 5, Motley Fool contributors Keith Speights and Brian Orelli discuss why Exact Sciences doesn't have to worry too much about declining COVID-19 testing rates impacting its growth.

Continue reading

Source Fool.com